Crossref journal-article
American Society for Microbiology
Journal of Virology (235)
Abstract

ABSTRACT We screened a panel of R5X4 and X4 human immunodeficiency virus type 1 (HIV-1) strains for their sensitivities to AMD3100, a small-molecule CXCR4 antagonist that blocks HIV-1 infection via this coreceptor. While no longer under clinical development, AMD3100 is a useful tool with which to probe interactions between the viral envelope (Env) protein and CXCR4 and to identify pathways by which HIV-1 may become resistant to this class of antiviral agents. While infection by most virus strains was completely blocked by AMD3100, we identified several R5X4 and X4 isolates that exhibited plateau effects: as the AMD3100 concentration was increased, virus infection and membrane fusion diminished to variable degrees. Once saturating concentrations of AMD3100 were achieved, further inhibition was not observed, indicating a noncompetitive mode of viral resistance to the drug. The magnitude of the plateau varied depending on the virus isolate, as well as the cell type used, with considerable variation observed when primary human T cells from different human donors were used. Structure-function studies indicated that the V1/V2 region of the R5X4 HIV-1 isolate DH12 was necessary for AMD3100 resistance and could confer this property on two heterologous Env proteins. We conclude that some R5X4 and X4 HIV-1 isolates can utilize the AMD3100-bound conformation of CXCR4, with the efficiency being influenced by both viral and host factors. Baseline resistance to this CXCR4 antagonist could influence the clinical use of such compounds.

Bibliography

Harrison, J. E., Lynch, J. B., Sierra, L.-J., Blackburn, L. A., Ray, N., Collman, R. G., & Doms, R. W. (2008). Baseline Resistance of Primary Human Immunodeficiency Virus Type 1 Strains to the CXCR4 Inhibitor AMD3100. Journal of Virology, 82(23), 11695–11704.

Authors 7 University of Pennsylvania
  1. Jessamina E. Harrison (first)
  2. Jonathan B. Lynch (additional)
  3. Luz-Jeannette Sierra (additional)
  4. Leslie A. Blackburn (additional)
  5. Neelanjana Ray (additional)
  6. Ronald G. Collman (additional) University of Pennsylvania
  7. Robert W. Doms (additional)
References 61 Referenced 16
  1. 10.1128/jvi.66.5.2934-2942.1992
  2. 10.1371/journal.ppat.0020010
  3. 10.1093/jac/dkl027
  4. 10.1128/JVI.72.3.2509-2515.1998
  5. 10.1128/jvi.70.10.7318-7321.1996
  6. 10.1038/nrd1134
  7. 10.1128/AAC.38.4.668
  8. 10.1128/jvi.70.2.689-696.1996
  9. 10.1128/AAC.41.12.2616
  10. 10.1038/nm0198-072
  11. 10.1016/S0092-8674(00)81393-8
  12. 10.1016/S0140-6736(07)61052-6
  13. 10.1016/S0092-8674(00)80577-2
  14. 10.1016/j.bcp.2006.05.010
  15. 10.1126/science.1070441
  16. 10.1128/JVI.79.21.13250-13261.2005
  17. 10.1172/JCI7403
  18. 10.1189/jlb.0306148
  19. 10.1016/j.virol.2006.11.025
  20. 10.1097/00002030-200109070-00010
  21. 10.1089/aid.2005.21.171
  22. 10.1128/JVI.78.14.7582-7589.2004
  23. 10.1097/01.qai.0000137371.80695.ef
  24. 10.1073/pnas.95.19.11360
  25. 10.1126/science.1145373
  26. 10.1128/JVI.77.24.13042-13052.2003
  27. 10.1016/j.virol.2007.02.022
  28. 10.1089/08892220152741414
  29. 10.1128/JVI.78.6.2790-2807.2004
  30. 10.1371/journal.ppat.0030117
  31. 10.1128/JVI.77.2.1610-1613.2003
  32. 10.1128/JVI.75.12.5457-5464.2001
  33. 10.1073/pnas.96.9.5215
  34. 10.1128/JVI.00385-07
  35. 10.1128/JVI.78.16.8654-8662.2004
  36. 10.1006/viro.2000.0807
  37. 10.1016/j.virol.2005.04.035
  38. 10.1016/j.virol.2004.07.019
  39. 10.1083/jcb.151.2.413
  40. 10.1038/nm0796-760
  41. 10.1089/088922204322749567
  42. 10.1128/JVI.01793-07
  43. 10.1128/JVI.79.7.4347-4356.2005
  44. 10.1016/j.virol.2006.11.004
  45. 10.1128/jvi.71.4.3219-3227.1997
  46. Ray, N., and R. W. Doms. 2006. HIV-1 coreceptors and their inhibitors. Curr. Top. Microbiol. Immunol.303:97-120. / Curr. Top. Microbiol. Immunol. (2006)
  47. 10.1128/JVI.02413-06
  48. 10.1073/pnas.252469399
  49. 10.1097/00002030-200109070-00004
  50. Rucker, J., B. J. Doranz, A. L. Edinger, D. Long, J. F. Berson, and R. W. Doms. 1997. Cell-cell fusion assay to study role of chemokine receptors in human immunodeficiency virus type 1 entry. Methods Enzymol.288:118-133. / Methods Enzymol. (1997)
  51. 10.1016/S0166-3542(97)00025-9
  52. 10.1084/jem.186.8.1383
  53. 10.1128/jvi.69.7.4453-4462.1995
  54. 10.1128/JVI.74.2.693-701.2000
  55. 10.1128/JVI.72.5.4478-4484.1998
  56. 10.1038/384184a0
  57. 10.1128/JVI.02006-06
  58. 10.1084/jem.185.9.1681
  59. 10.1128/JVI.73.9.7117-7125.1999
  60. 10.1080/753312758
  61. 10.1128/JVI.79.3.1480-1486.2005
Dates
Type When
Created 16 years, 11 months ago (Sept. 18, 2008, 10:38 a.m.)
Deposited 3 years, 5 months ago (March 5, 2022, 7:07 a.m.)
Indexed 1 year, 3 months ago (May 17, 2024, 8:49 a.m.)
Issued 16 years, 9 months ago (Dec. 1, 2008)
Published 16 years, 9 months ago (Dec. 1, 2008)
Published Print 16 years, 9 months ago (Dec. 1, 2008)
Funders 0

None

@article{Harrison_2008, title={Baseline Resistance of Primary Human Immunodeficiency Virus Type 1 Strains to the CXCR4 Inhibitor AMD3100}, volume={82}, ISSN={1098-5514}, url={http://dx.doi.org/10.1128/jvi.01303-08}, DOI={10.1128/jvi.01303-08}, number={23}, journal={Journal of Virology}, publisher={American Society for Microbiology}, author={Harrison, Jessamina E. and Lynch, Jonathan B. and Sierra, Luz-Jeannette and Blackburn, Leslie A. and Ray, Neelanjana and Collman, Ronald G. and Doms, Robert W.}, year={2008}, month=dec, pages={11695–11704} }